Notice NOT-NS-19-081 from the NIH Guide for Grants and Contracts

Adapts bioinformatic tools, visualization packages, and annotation resources for research projects to independently and accurately perform research analysis.
From Medical College of Wisconsin - Tue, 06 Aug 2019 15:07:30 GMT - View all Milwaukee, WI jobs

Competitive Salary: EMBL: Bio-IT Computational Support & Training Location: Germany (DE)

Competitive Salary: EMBL: Senior Software Engineer Location: Cambridge, Cambridgeshire, England

Not specified: CK Group: Natasha Young is currently recruiting for a Bioinformatician to join a dedicated team of researchers providing an outsourced service to Eli Lilly, one of the... Windlesham

Funding Opportunity PAR-19-328 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports applications to develop and implement investigator-initiated clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Clinical trials supported by this FOA include Phase II and above clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven mechanism of award. It is anticipated that applications will present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes the conduct of the trial, as well as plans for project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination. Due to the complex nature of conducting a clinical trial, applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application. Staff will be able to assist applicants in meeting the objectives of this FOA.

Funding Opportunity PAR-19-330 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports applications for a collaborating Data Coordinating Center (DCC) investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the definition of an NIH clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a cooperative agreement mechanism of award and runs in parallel with a companion FOA (PAR-19-NNN) that encourages applications for a collaborating Clinical Coordinating Center (CCC). The DCC application must be specific for the clinical trial being proposed in the collaborating CCC. The objective of the DCC application is to present a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a collaborating CCC application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.

Funding Opportunity PAR-19-329 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Data Coordinating Center (PAR-19-NNN). The objective of the CCC application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. Both a CCC application and a collaborating Data Coordinating Center (DCC) application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.

Funding Opportunity PAR-19-335 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The FOA aims to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R and D) not typically supported through Phase II or Phase IIB grants or contracts. This may include independent replication of key studies, Investigational New Drug (IND)-enabling studies, clinical studies, manufacturing costs, regulatory assistance, or a combination of services. Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the Small Business Concern (SBC) is expected to maintain oversight and management of the R and D throughout the award.

Funding Opportunity PAR-19-334 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The FOA aims to facilitate the transition of previously funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance not typically supported through Phase II or Phase IIB grants or contracts. This may include preparation of documents for a Food and Drug Administration (FDA) submission, development of an intellectual property strategy, and/or planning for a clinical trial. Although a significant amount of the work in a CRP award may be subcontracted to other organizations, the SBC is expected to maintain oversight and management of the R and D throughout the award. Clinical trials not accepted under this FOA.

Funding Opportunity PAR-19-333 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The FOA aims to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R and D) not typically supported through Phase II or Phase IIB grants or contracts. This may include independent replication of key studies, Investigational New Drug (IND)-enabling studies, clinical studies, manufacturing costs, regulatory assistance, or a combination of services. Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the Small Business Concern (SBC) is expected to maintain oversight and management of the R and D throughout the award.

Notice NOT-DE-19-012 from the NIH Guide for Grants and Contracts

Notice NOT-MH-19-040 from the NIH Guide for Grants and Contracts

Notice NOT-DE-19-011 from the NIH Guide for Grants and Contracts

Notice NOT-OD-19-131 from the NIH Guide for Grants and Contracts

Notice NOT-CA-19-066 from the NIH Guide for Grants and Contracts

Wellcome Sanger Institute: Salary in the region of £36,737- £44,451 (dependent on experience) plus excellent benefits Permanent/ Open Contract The Parasite genomics team at the Hinxton, Cambridgeshire, England

Notice NOT-OD-19-129 from the NIH Guide for Grants and Contracts

Build, document, and maintain computational pipelines for NGS data analysis including RNA-Seq, ChIP-Seq, DNase-Seq/ATAC-Seq, and Hi-C....
From West Virginia University - Thu, 01 Aug 2019 22:06:28 GMT - View all Morgantown, WV jobs

Competitive Salary: EMBL: Master Internship in Bioinformatics Location: Italy (IT)